DOCSLIB.ORG

European Approval Process Coverage Winners & Losers: a Deep-Dive Into the EMA’S PRIME Scheme

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
European Approval Process Coverage Winners & Losers: a Deep-Dive Into the EMA’S PRIME Scheme European Approval Process Coverage Winners & Losers: A Deep-Dive Into The EMA’s PRIME Scheme Executive Summary marketing approval, including Europe’s first two Nine of the 70 medicines for unmet medical CAR T-cell based treatments and some cutting- needs that have to date won a place on the edge gene therapies. European Medicines Agency’s PRIME scheme are now approved for sale in the EU, and two more In this article, the Pink Sheet explores how PRIME approvals are expected soon. Meanwhile, most has been faring in the four years it has been applications for a “priority medicine” designation operating. are still missing the mark. Optimizing Development Plans Developers of products that win a place on the scheme are offered enhanced support from the Drug developers are continuing to show a lot EMA to help them optimize their development of interest in the European Medicines Agency’s plans and they may also secure review under priority medicines (PRIME) scheme and the the agency’s accelerated assessment mechanism advantages it offers. when they file the marketing application for their product for evaluation. Since the scheme was launched in 2016, the EMA has received over 300 applications from The scheme has tough eligibility criteria. companies seeking a PRIME designation for their Applicants must convince the EMA that their early-stage investigational products. The aim of investigational product has the potential to the program is to get drugs for unmet medical benefit patients with an unmet medical need, needs to patients faster by helping developers based on early clinical data. optimize their development plans and increasing the likelihood of having their products fast-tracked As of late July 2020, the EMA had received when they are eventually filed for regulatory 308 applications for entry onto PRIME. Of the review. applications reviewed, 70 have won PRIME designation and 228 were turned down. Ten Almost half of the medicines that have been applications were discarded and not reviewed. accepted onto scheme have been advanced therapy medicinal products (ATMPs). PRIME- Crossing The Finishing Line designated products cover a wide range of Nine PRIME-designated products have so far therapeutic areas – with oncology and hematology received pan-EU marketing approval. These medicines making up the largest share. Most are include the CAR T-cell cancer therapies Kymriah being, or have been, developed almost equally by and Yescarta, and the gene therapies Zynteglo small and medium-sized enterprises (SMEs) and and Zolgensma for treating transfusion- bigger pharma companies. dependent β-thalassemia and spinal muscular atrophy respectively. The table below lists the nine To date, nine products that were awarded products that have been approved. PRIME designation have gone on to win pan-EU 2 / October 2020 © Informa UK Ltd 2020 (Unauthorized photocopying prohibited.) PRIME-Designated Products Approved In The EU As Of 17 August 2020 Six of the nine medicines were granted a accounting respectively for 27% and 19% of the conditional marketing authorization, which means total. Only five of the 32 applications targeting the companies are required to provide the EMA neurology have been accepted as have just two with more data post-approval. The products in of the 18 applications for cardiovascular diseases. question are: Rozlytrek, Hepcludex, Zynteglo, See bar char below for all the therapeutic areas in Zolgensma, Ervebo and Polivy. the applications. Oncology And Hematology Are The Winners Some 47% (33 products) of products accepted The applications that have been accepted onto the onto the scheme have been ATMPs. The EMA scheme cover a wide range of therapeutic areas, has previously observed that a large proportion with oncology and hematology medicines making of ATMPs are being developed by SMEs who up the largest share. Nineteen of the 70 PRIME- often lack experience of the regulatory approval designated drugs are for cancer and 13 are for process. treating hematology/hemostaseology conditions, 3 / October 2020 © Informa UK Ltd 2020 (Unauthorized photocopying prohibited.) Regarding the remaining product types, 19 submitting applications in these markets.” (Also are small molecules (which the EMA refers to see “Adu-CAN-umab? Reading The Tea Leaves as chemicals), 15 are biologicals and three are For Biogen’s US Filing For Alzheimer’s Drug” - Pink immunological drugs. Sheet, 10 Aug, 2020.) While PRIME-designated products are being – or Vocimagene Amiretrorepvec have been – developed almost equally by SMEs Another product withdrawn from the scheme was and bigger pharma companies, there have been a Tocagen’s gene therapy for high-grade glioma handful of applications from academia, but these (HGG), Toca 511 (vocimagene amiretrorepvec). have all been turned down. The company’s Toca 511/Toca FC treatment last year missed the primary endpoint of overall Ten of the 308 applications were discarded survival compared to standard of care treatment without having been reviewed because they were and all secondary endpoints in a Phase III trial. deemed to be outside the scope of the scheme Tocagen has since merged with dermatology firm or to have a format and content inadequate to Forte Biosciences, but a statement from the latter support their review. in June does not mention any future plans for the HGG treatment. No Guarantees Five PRIME-designations have been withdrawn Emapalumab at the request of the companies involved, mostly Getting on and staying on the scheme also does because they had discontinued development. not necessarily guarantee EU marketing approval. Withdrawal from the scheme does not necessarily Gamifant (emapalumab), from Swedish Orphan spell the end of the road for a product. Biovitrum (Sobi), received PRIME designation in May 2016 and a marketing authorization Aducanumab application (MAA) for the product was submitted For example, aducanumab, Biogen and Eisai’s to the EMA for review in September 2018. investigational drug for treating Alzheimer’s Having reviewed the MAA, the agency last disease was among the first products to win a month recommended against approving the PRIME designation. The anti-amyloid agent was potential treatment for primary hemophagocytic later withdrawn from the scheme after producing lymphohistiocytosis. Sobi, which has already poor results in Phase III trials. These results were received US approval for Gamifant, said it announced in May 2019 and the companies said would appeal against the EMA’s decision. (Also they were discontinuing Phase III trials. A few see “Sobi To Appeal Against EMA Rejection For months later, Biogen surprised everyone by saying Emapalumab” - Pink Sheet, 24 Jul, 2020.) that a further analysis of the trial data had shown positive results and plans to pursue regulatory Two More Approvals In The Wings approval for the product were on again. In July Another two PRIME-designated products are 2020, the company said it had completed the expected to be approved soon – GlaxoSmithKline’s submission of a biologics license application multiple myeloma drug, Blenrep (belantamab (BLA) to the US Food and Drug Administration mafodotin), and Hansa Biopharma’s Idefirix for the approval of aducanumab and that it “has (imlifidase), for the desensitization of continued to engage in dialogue with regulatory highly sensitized patients who need kidney authorities in other markets, including Europe transplantation but are unlikely to receive a and Japan, working diligently toward the goal of compatible transplant. The EMA recommended 4 / October 2020 © Informa UK Ltd 2020 (Unauthorized photocopying prohibited.) that Blenrep and Idefirix be granted EU marketing European Commission, which usually takes approval in July and June respectively. The around two months to issue a formal approval. agency’s recommendations are sent to the The Fate Of PRIME Applications 5 / October 2020 © Informa UK Ltd 2020 (Unauthorized photocopying prohibited.) PRIME Applications By Therapeutic Area As Of 23 July 2020* EGFM - Endocrinology-gynecology-fertility-metabolism; IRT - Immunology-rheumatology-transplantation; NPIC - Neonatology-pediatric intensive care. *Out of scope applications are not included in this chart. Source: EMA 6 / October 2020 © Informa UK Ltd 2020 (Unauthorized photocopying prohibited.) This Year seven months of 2020 and 2019 are also similar, There is continuing interest in PRIME. at 82% (28 applications denied) and 76% (23 denied) respectively. In 2020 to date, the EMA has reviewed a similar number of applications for PRIME compared with The latest investigational drugs to receive PRIME the same period last year. designation are Adaptimmune Therapeutics’ ADP-A2M4 cell therapy for synovial sarcoma and Between January and the end of July this year, Imago BioSciences’ myelofibrosis treatment, the agency reviewed 34 applications versus 30 bomedemstat. applications in the first seven months of 2019. Six investigational drugs have made it onto the The applications from the two companies scheme this year, compared with seven during the were among seven such requests that the EMA same time period in 2019, a year that culminated reviewed in July – the other five failed to make the in 16 PRIME designations being granted. grade. The table below lists all the products that have made it onto the scheme this year. The rejection rates for the applications in the first Products Granted PRIME Designation In Jan-July 2020 Most Applications Denied For example, Adaptimmune’s ADP-A2M4 was PRIME’s high rejection rate is perhaps to be accepted based on clinical data from a Phase expected. As noted by the EMA in its 2019 I trial, which the company said demonstrated annual report, published in June 2020, the “compelling efficacy and early promising scheme is intended for only the most promising durability, with tolerable safety in patients medicines and the agency focuses its attention on with synovial sarcoma.” Based on these data, products that have the potential to bring a major Adaptimmune initiated its Phase II SPEARHEAD-1 therapeutic advantage. trial of ADP-A2M4, enrolling patients with advanced synovial sarcoma and myxoid/round As such, the entry criteria are strict.
Load more

Recommended publications
  • HIV MARKET REPORT the State of HIV Treatment, Testing, and Prevention in Low- and Middle-Income Countries
    HIV MARKET REPORT The state of HIV treatment, testing, and prevention in low- and middle-income countries Issue 10, September 2019 Test Treat Stay Smart Right Negative This report was made possible through the generous support of Unitaid, with complementary support from the UK Department for International Development (DFID) and the Bill & Melinda Gates Foundation. Table of Contents Acronyms Used .................................................................................................................................................................... 4 Foreword .............................................................................................................................................................................. 5 2019 Market Report At-a-Glance ..................................................................................................................................... 6 GENERAL TRENDS ........................................................................................................................................................... 7 Figure 1: Major HIV Pricing Updates as of Sep. 2019 .......................................................................................................................... 7 Figure 2: Generic-accessible (GA) LMIC Weighted Average Regimen Price (USD, PPPY) .................................................... 7 Figure 3: HIV Resources in LMICs, 2000-2018 .....................................................................................................................................
    [Show full text]
  • 207931Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207931Orig1s000 OTHER REVIEW(S) MEMORANDUM REVIEW OF REVISED LABEL AND LABELING Division of Medication Error Prevention and Analysis (DMEPA) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Date of This Memorandum: July 22, 2015 Requesting Office or Division: Division of Antiviral Products (DAVP) Application Type and Number: NDA 207931 Product Name and Strength: Technivie (ombitasvir, paritaprevir, ritonavir) Tablets, 12.5 mg/75 mg/50 mg Submission Date: June 19, 2015 and July 2, 2015 Applicant/Sponsor Name: Abbvie OSE RCM #: 2015-497-1 DMEPA Primary Reviewer: Mónica Calderón, PharmD, BCPS DMEPA Team Leader: Vicky Borders-Hemphill, PharmD 1 PURPOSE OF MEMO Abbvie has submitted the revised container label and carton labeling (Appendix A) for Technivie in response to recommendations we made during a previous label and labeling review. 1 Abbvie also submitted a response on June 19, 2015 to fulfill our request for the lot number and expiration date to be placed on the immediate container. Thus, the Division of Antiviral Products (DAVP) requested that we review the revised label and labeling to determine if it is acceptable from a medication error perspective. 2 CONCLUSIONS The revised container label and carton labeling is acceptable from a medication error perspective. The lot number and expiration date are printed on-line (i.e. as the product is 1 Calderon M. Label and Labeling Review for PRODUCT NAME (NDA 207931). Silver Spring (MD): Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, Division of Medication Error Prevention and Analysis (US); 2015 05 19.
    [Show full text]
  • FDA Fast Track and Priority Review Programs
    Order Code RS22814 February 21, 2008 FDA Fast Track and Priority Review Programs Susan Thaul Specialist in Drug Safety and Effectiveness Domestic Social Policy Division Summary By statutory requirements and by regulation, guidance, and practice, the Food and Drug Administration (FDA) works with several overlapping yet distinct programs to get to market quickly new drug and biological products that address unmet needs. FDA most frequently uses three mechanisms for that purpose: Accelerated Approval, Fast Track, and Priority Review. The first two affect the development process before a sponsor submits a marketing application. Accelerated Approval allows surrogate endpoints in trials to demonstrate effectiveness and is relevant in fewer situations than the others. The Fast Track program encourages a sponsor to consult with FDA while developing a product. Unlike the others, Priority Review involves no discussions of study design or procedure; it relates only to an application’s place in the review queue. Analysis of total approval time for approved applications under the Fast Track and Priority Review programs shows that for seven of the past nine years, Fast Track products have shorter median approval times than do all those applications assigned to Priority Review. It takes an average of 15 years from the moment a manufacturer first approaches the Food and Drug Administration (FDA) with an idea for a new drug to its final approval for marketing.1 Steps in the development and approval of a drug or biologic (e.g., a vaccine) involve actions by both the manufacturer and FDA. First, a manufacturer (sometimes referred to as the sponsor) submits to FDA an Investigational New Drug (IND) application for permission to conduct clinical studies in humans.
    [Show full text]
  • FDA Approves Lilly's LARTRUVO™ (Olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma
    October 19, 2016 FDA Approves Lilly's LARTRUVO™ (olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma -- LARTRUVO, in combination with doxorubicin, is the first FDA-approved front-line therapy for soft tissue sarcoma in four decades -- The approval was based on results from the positive Phase 2 JGDG trial -- LARTRUVO received the FDA's Breakthrough Therapy Designation and was approved under the Agency's Accelerated Approval program INDIANAPOLIS, Oct. 19, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of LARTRUVO™ (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline- containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. LARTRUVO's indication is approved under Accelerated Approval, and is based on data from the Phase 2 portion of the pivotal JGDG trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. LARTRUVO, in combination with doxorubicin, is the first FDA-approved front-line therapy for STS in four decades. The confirmatory Phase 3 trial, ANNOUNCE, is fully enrolled. "LARTRUVO represents an important step forward in soft tissue sarcoma treatment," said William D. Tap, M.D., chief of the sarcoma medical oncology services at Memorial Sloan Kettering Cancer Center in New York and the principal investigator of the JGDG registration trial. "We are pleased with this approval, which will provide patients with a treatment option that offers new hope in their battle against this difficult disease." Soft tissue sarcoma is a complex disease with multiple subtypes, making it hard to diagnose and difficult to treat.
    [Show full text]
  • Download FDA's Expedited Drug Approval Programs
    Expedited Drug Approval Programs The process for collecting evidence in support of a new drug approval involves multiple steps. Drug developers (sponsors) collect evidence during pre-clinical and clinical phases of the process and submit it to the U.S. Food and Drug Administration (FDA) for evaluation of the drug’s safety and efficacy. The next step is a final review for marketing authorization which occurs when a drug sponsor submits a New Drug Application (NDA) to FDA for small molecule drugs or a Biologics Licensing Application (BLA) for biologics. FDA follows a standard review process – which typically takes up to 10 months – to determine whether to approve the drug. Throughout this process, from drug development to post- market monitoring, there are various points in which drug sponsors and FDA interact and exchange information. The time it takes for drug development and approval varies by drug and therapeutic area and FDA review is only part of this process. In most cases, most of this time is spent by drug sponsors in the data collection phases, e.g. clinical trials. But not all approvals follow the standard review process. Drug therapies that address unmet medical needs, treat serious or life-threatening conditions, or show a significant advantage over current therapies may be eligible for one or more of FDA’s four Expedited Review Programs. These programs are designed to accelerate the approval process and make the therapies available to patients quicker if it is determined the therapies’ benefits justify their risks.1 The four Expedited Review Programs are Priority Review, Accelerated Approval, Fast Track, and Breakthrough Therapy.
    [Show full text]
  • FDA Fast Track and Priority Review Programs
    FDA Fast Track and Priority Review Programs February 21, 2008 Congressional Research Service https://crsreports.congress.gov RS22814 FDA Fast Track and Priority Review Programs Summary By statutory requirements and by regulation, guidance, and practice, the Food and Drug Administration (FDA) works with several overlapping yet distinct programs to get to market quickly new drug and biological products that address unmet needs. FDA most frequently uses three mechanisms for that purpose: Accelerated Approval, Fast Track, and Priority Review. The first two affect the development process before a sponsor submits a marketing application. Accelerated Approval allows surrogate endpoints in trials to demonstrate effectiveness and is relevant in fewer situations than the others. The Fast Track program encourages a sponsor to consult with FDA while developing a product. Unlike the others, Priority Review involves no discussions of study design or procedure; it relates only to an application’s place in the review queue. Analysis of total approval time for approved applications under the Fast Track and Priority Review programs shows that for seven of the past nine years, Fast Track products have shorter median approval times than do all those applications assigned to Priority Review. Congressional Research Service FDA Fast Track and Priority Review Programs Contents Mechanisms to Expedite the Development and Review Process .................................................... 1 Accelerated Approval ...............................................................................................................
    [Show full text]
  • (Olaratumab) for Soft Tissue Sarcoma By: Majd Abedrabbo, Pharmd Candidate 2018 Fairleigh Dickinson University School of Pharmacy May 3, 2017
    Drug Comparison: LartruvoTM (Olaratumab) for Soft Tissue Sarcoma By: Majd Abedrabbo, PharmD Candidate 2018 Fairleigh Dickinson University School of Pharmacy May 3, 2017 Introduction Soft Tissue Sarcoma (STS) is a rare type of cancer with multiple treatment options. There are approximately 12,390 new cases of STS diagnosed and 4,990 Americans are estimated to die each year in the United States. The standard of care for patients with metastatic STS is treatment with doxorubicin, an anthracycline that was approved in 1974 and is associated with significant toxicity, including myelosuppression, the development of secondary cancers, and dose-limiting cardiotoxicity. Other treatment options include targeted therapies, which interfere with mutated or over-active proteins that drive the cancer. In this article, we compare doxorubicin (Adriamycin), the standard of care, chemotherapeutic agent, with Olaratumab (Lartruvo), a new targeted therapy. Background STS is a collection of cancers of tissues that connect and support the body, like fat cells and blood vessels, which are of mesenchymal origin.1 Since sarcomas need not invade the basement membrane, they have a very high metastatic potential, capable of spreading throughout the body with relative ease. Risk factors of STS include specific genetic diseases, radiation treatments for other cancers, and exposure to chemicals.2 Although there are more than 50 types of STS, the most common types in adults are undifferentiated pleomorphic sarcoma, liposarcoma, and leiomyosarcoma.3 The risk and severity of STS depends on the type, which is dependent upon the location, specific cell of origin, stage of differentiation, and mutations. The standard of care for patients with metastatic STS is treatment with doxorubicin, which disrupts topoisomerase II by intercalating into the DNA, preventing DNA replication and transcription, thereby inducing apoptosis.4 It can be used as 1 monotherapy or in combination with other drugs.
    [Show full text]
  • JULY 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
    JULY 2019 MRx Pipeline A view into upcoming specialty and traditional drugs TABLE OF CONTENTS EDITORIAL STAFF Introduction Maryam Tabatabai, PharmD Editor in Chief Senior Director, Drug Information Pipeline Deep Dive Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Keep on Your Radar Consultant Panel Michelle Booth, Pharm D Director, Medical Pharmacy Strategy Becky Borgert, PharmD, BCOP Pipeline Drug List Director, Clinical Oncology Product Development Lara Frick, PharmD, BCPS, BCPP Drug Information Pharmacist Glossary Robert Greer, RPh, BCOP Senior Director, Clinical Strategy and Programs YuQian Liu, PharmD Manager, Specialty Clinical Programs Troy Phelps Senior Director, Analytics Nothing herein is or shall be construed as a promise or representation regarding past or future events and Magellan Rx Management expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Magellan Rx Management. 1 | magellanrx.com INTRODUCTION Welcome to the MRx Pipeline. In its third year of publication, this quarterly report offers clinical insights and competitive intelligence on anticipated drugs in development. Our universal forecast addresses trends applicable across market segments. Traditional and specialty drugs, agents under the pharmacy and medical benefits, new molecular entities, pertinent new and expanded indications for existing medications, and biosimilars are profiled in the report.
    [Show full text]
  • Accelerated Approval for Soft Tissue Sarcoma Treatment
    Accelerated Approval for Soft Tissue Sarcoma Treatment he FDA granted accelerated ap- effects of treatment with olaratumab tion, breakthrough therapy designation, proval program, which allows approval proval to olaratumab (Lartruvo) are nausea, fatigue, neutropenia, mus- and priority review status because pre- of a drug to treat a serious or life- Twith doxorubicin to treat adults with culoskeletal pain, mucositis, alopecia, liminary clinical evidence indicated it threatening disease or condition based certain types of soft tissue sarcoma (STS). vomiting, diarrhea, decreased appe- may offer a substantial improvement on clinical data showing the drug has Olaratumab is approved for use with tite, abdominal pain, neuropathy, and in effectiveness in the treatment of a an effect on a surrogate endpoint that is the FDA-approved chemotherapy drug headache. serious or life-threatening disease or reasonably likely to predict clinical ben- doxorubicin for the treatment of patients The FDA granted the olara- condition. The FDA is approving the efit. Olaratumab also received orphan with STS who cannot be cured with ra- tumab application fast track designa- drug under the agency’s accelerated ap- drug designation. OT diation or surgery and who have a type of STS for which an anthracycline is an appropriate treatment. “For these patients, Lartruvo, added to doxorubicin, provides a new treat- ment option,” said Richard Pazdur, MD, Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research and Acting Director of the FDA’s Oncology Center of Excellence. “This is the first new therapy approved by the FDA for the initial treat- ment of soft tissue sarcoma since doxoru- bicin’s approval more than 40 years ago.” The NCI estimates that 12,310 new cases of STS and nearly 5,000 deaths are likely to occur from the disease in 2016.
    [Show full text]
  • Overview of U.S. FDA Center for Biologics Evaluation and Research
    Overview of U.S. FDA Center for Biologics Evaluation and Research David Martin, M.D., M.P.H. Director, Division of Epidemiology Center for Biologics Evaluation and Research US Food and Drug Administration Application of Pharmacovigilance to U.S. FDA Regulatory Decisions for Vaccines June 2, 2012 Outline . FDA: a regulatory agency granted the authority to ensure that U.S. licensed vaccines are safe and effective . Structure of FDA and the Center for Biologics Evaluation and Research . Historical timeline of the expansion of vaccine regulation in the United States (optional topic) 2 FDA Legal Framework Statutes (enacted by Congress, signed by President) Regulations (FDA) 3 Main Statutes Pertinent to Vaccine Safety . Federal Food, Drug and Cosmetic Act . Amended by the Food and Drug Administration Amendments Act of 2007 . Public Health Service Act . National Childhood Vaccine Injury Act 4 US Code of Federal Regulations (CFR) FDA implements statutes through regulations • 21 CFR 600-680 Biological Product Standards • 21 CFR 314.126 Adequate and well-controlled trials • 21 CFR 312 Investigational New Drug Application • 21 CFR 210-211 Good Manufacturing Practices • 21 CFR 58 Good Laboratory Practices • 21 CFR 56 Institutional Review Boards • 21 CFR 50 Protection of Human Subjects 5 National Childhood Vaccine Injury Act . Designed to stabilize supply and cost of vaccines by addressing liability . Created a “no fault” compensation system . The vaccine injury table lists conditions presumed to be caused by vaccines within specific timeframes . Financed through excise tax on recommended vaccine products . Created additional U.S. vaccine safety infrastructure . National Vaccine Program Office to coordinate HRSA, CDC, FDA, NIH .
    [Show full text]
  • Inhaled Antimicrobial Therapy – Barriers to Effective Treatment☆
    Advanced Drug Delivery Reviews 85 (2015) 24–43 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Inhaled antimicrobial therapy – Barriers to effective treatment☆ Jeffry Weers Novartis Pharmaceuticals Corporation, 150 Industrial Road, San Carlos, CA, USA article info abstract Available online 1 September 2014 Inhaled antibiotics dramatically improve targeting of drug to the site of respiratory infections, while simulta- neously minimizing systemic exposure and associated toxicity. The high local concentrations of antibiotic may Keywords: enable more effective treatment of multi-drug resistant pathogens. This review explores barriers to effective Biofilm treatment with inhaled antibiotics. In addition, potential opportunities for improvements in treatment are Dry powder inhaler reviewed. Endpoint © 2014 Elsevier B.V. All rights reserved. Fixed dose combination Nebulizer Partial liquid ventilation Tolerability Contents 1. Introduction...............................................................25 1.1. Chronic infections in cystic fibrosis(CF)...............................................25 1.2. Chronicinfectionsinnon-CFbronchiectasis(NCFBE)..........................................26 1.3. Acuteexacerbationsinchronicobstructivepulmonarydisease(AECOPD)................................26 1.4. Ventilator-associatedpneumonia(VAP)...............................................27 1.5. Otherinfections..........................................................27 1.6. Barrierstodevelopmentofinhaledantibiotics............................................27
    [Show full text]
  • 2021 PPO Annual Notice of Change (PDF)
    Aetna MedicareSM Plan (PPO) offered by Aetna Life Insurance Company Annual Notice of Changes for 2021 You are currently enrolled as a member of Aetna Medicare Plan (PPO). Next year, there will be some changes to the plan’s costs and benefits. This booklet tells about the changes. What to do now 1. ASK: Which changes apply to you £ Check the changes to our benefits and costs to see if they affect you. • It’s important to review your coverage now to make sure it will meet your needs next year. • Do the changes affect the services you use? • Look in Sections 1.5 and 1.6 for information about benefit and cost changes for our plan. £ Check the changes in the booklet to our prescription drug coverage to see if they affect you. • Will your drugs be covered? • Are your drugs in a different tier, with different cost sharing? • Do any of your drugs have new restrictions, such as needing approval from us before you fill your prescription? • Can you keep using the same pharmacies? Are there changes to the cost of using this pharmacy? • Review the 2021 Drug List and look in Section 1.6 for information about changes to our drug coverage. • Your drug costs may have risen since last year. Talk to your doctor about lower cost alternatives that may be available for you; this may save you in annual out-of-pocket costs throughout the year. To get additional information on drug prices visit go.medicare.gov/drugprices. These dashboards highlight which manufacturers have been increasing their prices and also show other year-to-year drug price information.
    [Show full text]